Nanjoo Suh Selected Research

bardoxolone

1/2014	A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
11/2007	CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.
6/2006	The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells.
6/2005	Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
4/2004	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
12/2003	Efficient synthesis of (-)- and (+)-tricyclic compounds with enone functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents.
7/2003	The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.
5/2002	The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells.
1/2002	Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nanjoo Suh Research Topics

Disease

56	Neoplasms (Cancer) 03/2021 - 01/2002
34	Breast Neoplasms (Breast Cancer) 03/2021 - 10/2002
27	Carcinogenesis 01/2020 - 07/2006
9	Colonic Neoplasms (Colon Cancer) 01/2017 - 01/2007
7	Neoplasm Metastasis (Metastasis) 01/2021 - 03/2011
5	Prostatic Neoplasms (Prostate Cancer) 03/2013 - 10/2006
4	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 06/2014
4	Adenocarcinoma 01/2017 - 10/2006
4	Inflammation (Inflammations) 03/2016 - 10/2002
4	Aberrant Crypt Foci 01/2013 - 01/2007
3	Hyperplasia 09/2015 - 11/2011
3	Body Weight (Weight, Body) 03/2011 - 01/2007
3	Leukemia 06/2006 - 05/2002
2	Triple Negative Breast Neoplasms 10/2017 - 01/2014
2	Prostatic Intraepithelial Neoplasia 02/2016 - 10/2006
2	Lung Neoplasms (Lung Cancer) 01/2013 - 01/2002
2	Insulin Resistance 07/2009 - 10/2008
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2007 - 01/2002
2	Myeloid Leukemia (Leukemia, Myelocytic) 06/2006 - 01/2002
1	Obesity 06/2022
1	Non-alcoholic Fatty Liver Disease 10/2021
1	Breast Ductal Carcinoma 01/2020
1	Colitis 01/2017
1	Ductal Carcinoma 06/2014

Drug/Important Bio-Agent (IBA)

19	Tocopherols (Tocopherol)IBA 01/2020 - 01/2007
13	Vitamin D FDA LinkGeneric 01/2020 - 07/2006
11	TriterpenesIBA 01/2014 - 01/2002
10	1,25- dihydroxy- 21- (3- hydroxy- 3- methyl- 4,4,4- tributyl)- 23- yne- 26,27- hexafluorocholecalciferolIBA 01/2020 - 07/2010
9	Estrogens (Estrogen)FDA Link 03/2021 - 06/2009
9	Vitamin E FDA LinkGeneric 01/2020 - 06/2009
9	bardoxoloneIBA 01/2014 - 01/2002
8	Proteins (Proteins, Gene)FDA Link 01/2013 - 06/2002
6	Biological ProductsIBA 03/2021 - 10/2008
6	Proliferating Cell Nuclear Antigen (PCNA)IBA 12/2017 - 01/2007
6	AntioxidantsIBA 03/2017 - 04/2009
6	Estrogen ReceptorsIBA 10/2016 - 05/2004
6	1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA 01/2014 - 07/2003
5	CarcinogensIBA 01/2017 - 10/2002
5	StilbenesIBA 09/2010 - 01/2007
5	AcidsIBA 11/2007 - 05/2002
4	AzoxymethaneIBA 01/2013 - 01/2007
4	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 11/2012 - 10/2002
4	pterostilbeneIBA 07/2010 - 01/2007
3	hydroxide ionIBA 01/2020 - 04/2015
3	Biomarkers (Surrogate Marker)IBA 10/2017 - 04/2009
3	CytokinesIBA 03/2016 - 07/2009
3	LigandsIBA 05/2013 - 06/2002
3	Cholecalciferol (Vitamin D3)FDA Link 01/2013 - 07/2006
3	Caspase 3 (Caspase-3)IBA 11/2012 - 05/2002
3	Cyclin D1IBA 01/2012 - 07/2010
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 11/2011 - 07/2007
3	ResveratrolIBA 09/2010 - 10/2008
3	alpha-Tocopherol FDA Link 04/2010 - 04/2009
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2009 - 05/2002
3	EnzymesIBA 04/2009 - 02/2004
3	Selective Estrogen Receptor Modulators (SERM)IBA 10/2006 - 10/2002
3	LY 353381 (LY353381)IBA 10/2006 - 10/2002
3	LG 100268IBA 10/2006 - 10/2002
2	RNA (Ribonucleic Acid)IBA 01/2020 - 12/2017
2	TocotrienolsIBA 01/2020 - 04/2010
2	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 01/2017 - 02/2016
2	benzocycloheptapyridineIBA 01/2017 - 02/2016
2	ErbB Receptors (EGF Receptor)IBA 10/2015 - 09/2013
2	PhytochemicalsIBA 03/2013 - 10/2008
2	NF-kappa B (NF-kB)IBA 07/2010 - 05/2002
2	gamma-TocopherolIBA 04/2010 - 04/2009
2	CholesterolIBA 07/2009 - 10/2008
2	PPAR gammaIBA 06/2009 - 06/2002
2	Transforming Growth Factor beta (TGF-beta)IBA 12/2007 - 05/2004
2	Caspase 8 (Caspase-8)IBA 06/2005 - 05/2002
2	Pharmaceutical PreparationsIBA 05/2004 - 12/2003
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2003 - 10/2002
2	bardoxolone methylIBA 01/2002 - 01/2002
1	tanshinoneIBA 06/2022
1	Histones (Histone)IBA 10/2021
1	Endocrine DisruptorsIBA 03/2021
1	bisphenol AIBA 03/2021
1	ElementsIBA 01/2021
1	Keratin-5 (Keratin 5)IBA 10/2017
1	3-nitrotyrosineIBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2017
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2017
1	Dextrans (Dextran)FDA Link 01/2017
1	anthraceneIBA 10/2016
1	Phenobarbital (Luminal)FDA Link 10/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2016
1	Free RadicalsIBA 10/2016
1	Interleukin-6 (Interleukin 6)IBA 03/2016
1	Lapatinib (GW572016)FDA Link 10/2015
1	Trastuzumab (Herceptin)FDA Link 10/2015
1	Epithelial Cell Adhesion MoleculeIBA 04/2015
1	Calcitriol Receptors (Calcitriol Receptor)IBA 06/2014
1	KalininIBA 06/2014
1	Phosphotransferases (Kinase)IBA 09/2013

Therapy/Procedure

10	Therapeutics 01/2021 - 06/2002
4	Chemoprevention 01/2020 - 07/2002
2	Drug Therapy (Chemotherapy) 01/2021 - 07/2008
1	Transplantation 01/2021
1	Complementary Therapies (Alternative Medicine) 10/2016
1	Treatment Delay 09/2013